Welcome to our dedicated page for Essa Pharma SEC filings (Ticker: EPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page aggregates historical SEC filings for ESSA Pharma Inc. (former NASDAQ: EPIX), a British Columbia–incorporated pharmaceutical company that was previously focused on developing novel and proprietary therapies for patients with prostate cancer. These filings document ESSA’s regulatory history as a U.S.-reporting issuer and provide detailed information on the corporate steps that led to its acquisition by XenoTherapeutics Inc. and the delisting of its common shares.
Among the key documents available are multiple Forms 8-K reporting material events related to the Business Combination Agreement with XenoTherapeutics, the subsequent Amendment Agreement, and the consummation of the court-approved plan of arrangement under the Business Corporations Act (British Columbia). These filings describe the consideration received by ESSA shareholders, including cash payments and non-transferable contingent value rights (CVRs), as well as the company’s large return of capital distribution made as part of the discontinuance and winding-up of its business.
The filings also include a Form 25 (Form 25-NSE) filed by Nasdaq Stock Market LLC on October 9, 2025, which formally removes ESSA’s common stock from listing and registration on Nasdaq. Related 8-K disclosures explain ESSA’s request that Nasdaq suspend trading in its shares and the purchaser’s intention to file a Form 15 to terminate registration under Section 12(g) of the Exchange Act and suspend reporting obligations under Sections 13 and 15(d).
Using Stock Titan’s tools, readers can quickly locate ESSA’s quarterly and annual reports, current reports on Form 8-K, and transaction-related exhibits, while AI-powered summaries help interpret complex legal and financial language. This makes it easier to understand how the arrangement was structured, how shareholder votes and court approvals were obtained, and what the delisting and deregistration steps mean for the historical EPIX ticker and former ESSA securityholders.
ESSA Pharma Inc. (EPIX) released additional proxy-soliciting materials (DEFA14A) describing a Business Combination Agreement dated 13 July 2025 under which Xeno Acquisition Corp., a subsidiary of XenoTherapeutics, will acquire all outstanding ESSA common shares via a British Columbia court-approved plan of arrangement.
Consideration: Each shareholder will receive (i) a cash payment equal to ESSA’s net cash at 12:01 a.m. Vancouver time on closing, less a US$4 million transaction fee, liabilities reserve and expenses, divided by outstanding shares (the “Cash Amount”), and (ii) one non-transferable contingent value right (CVR). The CVR could pay up to (a) US$2.8 million minus legal costs incurred within 18 months and (b) US$150 000 minus additional liabilities. Management currently estimates the combined initial distribution and closing cash at ≈US$1.90 per share, exclusive of any CVR proceeds.
- In-the-money options and warrants will be cashed out for the Cash Amount minus exercise price plus one CVR; all options are expected to be out-of-the-money at closing and will be cancelled without payment.
- ESSA will delist from Nasdaq and deregister under the U.S. Exchange Act; the company will also seek to cease reporting in British Columbia, Alberta and Ontario.
- A special meeting to vote on the arrangement must occur on or before 8 September 2025; closing is targeted for 2H 2025 and within three business days of the final court order.
- Deal failure would leave shareholders without consideration, while ESSA would continue to pursue a wind-up and could owe a US$2.5 million termination fee.
- Registered shareholders may exercise dissent rights; U.S. and Canadian tax summaries, meeting logistics and detailed procedures will appear in the forthcoming circular.
Key risks: completion uncertainty, variable cash amount, non-transferable CVRs, delisting/loss of future upside, and litigation or regulatory delays.